CD40/CD40 ligand interactions have been demonstrated to be critical co-stimulatory molecules in the generation of a successful immune response. We hypothesized that it may be possible to augment the immunostimulatory effects of CD40 stimulation by combining it with cytokine therapy. IL2 has been demonstrated to augment both adaptive and innate immune responses. Thus far, cytokine therapy has concentrated on using combinations of cytokines. We reasoned that the use of CD40 stimulation to promote dendritic cell development and function coupled with the properties of IL2 to promote T cell function would result in synergistic anti-tumor effects in vivo. Using a highly metastatic murine renal cancer model we found that strong synergistic anti-tumor effects resulted if CD40 stimulation was applied with IL2 therapy whereas no effect was observed using either agent alone. We now propose to delineate the mechanism underlying these anti-tumor effects and optimize the immunotherapeutic potential of this regimen. Toward this goal we have developed 5 specific aims:
Specific Aim 1 will assess the effects of CD40 stimulation using agonist antibodies to CD40 in combination with IL2 on various metastatic renal tumor models (using both CD40+ and CD40- tumor lines) to determine the extent at which this approach is efficacious and to determine if specific immunity results upon rechallenge.
Specific Aim 2 will explore the immunomodulatory effects of this regimen through the assessment of various components of both the innate (dendritic, NK) and adaptive (T and B) immune system as well as the role of cytokines.
Specific Aim 3 will determine the role of CD40 on various tissues in response to this regimen through the use of CD40 -/- mice and various chimeras constructed by them.
Specific Aim 4 will ascertain the efficacy of a recombinant soluble ligand for CD40 (srCD40L) to determine if similar immunomodulatory and anti-tumor effects can be obtained with this combination with IL2, particularly in light of recent data demonstrating extreme toxicities associated with antibodies to CD40 given after cytoreductive conditioning.
Specific Aim 5 will then examine the effects of CD40 stimulation and IL2 in models in which cytoreductive conditioning is applied to advanced tumor-bearing mice. Both potential toxicities (which will be sought to be overcome), effects on immune reconstitution, and anti-tumor effects will be evaluated. This last model will most closely resemble advanced tumor bearing patients undergoing a debulking procedure followed with immunotherapy to remove the minimal residual disease. This proposal examining induction of costimulation with CD40 followed with IL2, should yield significant insights, not only to the efficacy of this combination approach in cancer, but also as an immunostimulatory regimen for infectious disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA095572-02
Application #
6650860
Study Section
Special Emphasis Panel (ZRG1-ET-1 (03))
Program Officer
Mccarthy, Susan A
Project Start
2002-09-01
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
2
Fiscal Year
2003
Total Cost
$290,363
Indirect Cost
Name
University of Nevada Reno
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
146515460
City
Reno
State
NV
Country
United States
Zip Code
89557
Aguilar, Ethan G; Murphy, William J (2018) Obesity induced T cell dysfunction and implications for cancer immunotherapy. Curr Opin Immunol 51:181-186
Sckisel, Gail D; Mirsoian, Annie; Minnar, Christine M et al. (2017) Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. J Immunother Cancer 5:33
Monjazeb, Arta M; Kent, Michael S; Grossenbacher, Steven K et al. (2016) Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. Clin Cancer Res 22:4328-40
Mall, Christine; Sckisel, Gail D; Proia, David A et al. (2016) Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology 5:e1075114
Sckisel, Gail D; Mirsoian, Annie; Bouchlaka, Myriam N et al. (2015) Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. Cancer Immunol Immunother 64:1541-52
Mirsoian, Annie; Murphy, William J (2015) Obesity and cancer immunotherapy toxicity. Immunotherapy 7:319-22
Erdembileg, Anuurad; Mirsoian, Annie; Enkhmaa, Byambaa et al. (2015) Attenuated age-impact on systemic inflammatory markers in the presence of a metabolic burden. PLoS One 10:e0121947
Zamora, Anthony E; Grossenbacher, Steven K; Aguilar, Ethan G et al. (2015) Models to Study NK Cell Biology and Possible Clinical Application. Curr Protoc Immunol 110:14.37.1-14
Sckisel, Gail D; Bouchlaka, Myriam N; Monjazeb, Arta M et al. (2015) Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. Immunity 43:240-50
Monjazeb, Arta M; Tietze, Julia K; Grossenbacher, Steven K et al. (2014) Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. PLoS One 9:e102709

Showing the most recent 10 out of 29 publications